Literature DB >> 10954022

The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.

T Shimoike1, T Inoguchi, F Umeda, H Nawata, K Kawano, H Ochi.   

Abstract

It has been reported that advanced glycosylation end products (AGEs) play an important role in the development of diabetic complications. To evaluate the relationship between serum AGEs and diabetic nephropathy, we measured serum AGE levels in diabetic patients with normoalbuminuria (N), microalbuminuria (M), overt proteinuria (O), and hemodialysis (HD), non diabetic patients with nephropathy, and age-matched control subjects using the enzyme-linked immunosorbent assay (ELISA). Urine AGE levels were also measured in these subjects except group HD. Serum AGE levels in diabetic patients were not significantly higher than those in the normal subjects. When we compared serum AGE levels among various stages of diabetic nephropathy, groups O and HD had significantly higher serum AGE levels than the other groups. Serum AGE levels in group HD were almost 6-fold higher than those in groups N and M. In contrast, there were no significant differences in urinary AGE levels among any diabetic groups. As for the variables that determine serum AGE levels in diabetic patients, there was no significant correlation between serum AGEs and fasting blood glucose, hemoglobin A1c (HbA1c), or duration of diabetes. In contrast, serum AGEs showed a strong correlation with serum creatinine and an inverse correlation with creatinine clearance. To evaluate the relationship between serum AGEs and oxidative stress in diabetic nephropathy, urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG) and serum malondialdehyde (MDA), which are biological markers of total oxidative stress in vivo, were also examined. Both urinary 8-OHdG and serum MDA levels were significantly higher in diabetic patients with proteinuria versus those without proteinuria. However, there was no significant correlation between serum AGEs and urinary 8-OHdG or serum MDA levels in diabetic patients. These results suggest that the accumulation of serum AGEs in diabetic nephropathy may be mainly due to decreased removal in the kidney rather than increased production by high glucose levels or oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954022     DOI: 10.1053/meta.2000.7738

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  28 in total

1.  Deletion of platelet-derived growth factor receptor-β improves diabetic nephropathy in Ca²⁺/calmodulin-dependent protein kinase IIα (Thr286Asp) transgenic mice.

Authors:  H Suzuki; I Usui; I Kato; T Oya; Y Kanatani; Y Yamazaki; S Fujisaka; S Senda; Y Ishii; M Urakaze; A Mahmood; S Takasawa; H Okamoto; M Kobayashi; K Tobe; M Sasahara
Journal:  Diabetologia       Date:  2011-08-11       Impact factor: 10.122

2.  cagA and vacA status and influence of Helicobacter pylori infection on serum oxidative DNA damage in Iranian patients with peptic ulcer disease.

Authors:  Z Khodaii; S M H Ghaderian; R Akbarzadeh Najar; H Nejati; A S Tabatabaei Panah
Journal:  Ir J Med Sci       Date:  2010-08-20       Impact factor: 1.568

3.  Clinical efficacy of 'Spleen-kidney-care' Yiqi Huayu and Jiangzhuo traditional Chinese medicine for the treatment of patients with diabetic nephropathy.

Authors:  Hong Liu; Jin Zheng; Rong-Heng Li
Journal:  Exp Ther Med       Date:  2015-07-07       Impact factor: 2.447

4.  Chronic oxidative stress as a mechanism for radiation nephropathy.

Authors:  Marek Lenarczyk; Eric P Cohen; Brian L Fish; Amy A Irving; Mukut Sharma; Collin D Driscoll; John E Moulder
Journal:  Radiat Res       Date:  2009-02       Impact factor: 2.841

5.  Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes.

Authors:  J C Wu; X H Li; Y D Peng; J B Wang; J F Tang; Y F Wang
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

6.  Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.

Authors:  C Wihler; S Schäfer; K Schmid; E K Deemer; G Münch; M Bleich; A E Busch; T Dingermann; V Somoza; J W Baynes; J Huber
Journal:  Diabetologia       Date:  2005-07-12       Impact factor: 10.122

7.  Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus.

Authors:  M E Garay-Sevilla; J C Regalado; J M Malacara; L E Nava; K Wróbel-Zasada; A Castro-Rivas; K Wróbel
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

8.  The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1.

Authors:  M G A van Eupen; M T Schram; H M Colhoun; N M J Hanssen; H W M Niessen; L Tarnow; H H Parving; P Rossing; C D A Stehouwer; C G Schalkwijk
Journal:  Diabetologia       Date:  2013-04-26       Impact factor: 10.122

9.  Comparison of Periodontal Ligament Cell Lines with Adenovirus- and Lentivirus-Mediated Human Telomerase Reverse Transcription Expression.

Authors:  Guijun Sun; Yang Yang; Xiaoyan Lu; Qing Liu; Shengrong Wu; Jiajia Jin; Zixiao Huang; Xiangyi He
Journal:  Hum Gene Ther Methods       Date:  2019-02-28       Impact factor: 2.396

10.  Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation.

Authors:  A M Buongiorno; S Morelli; E Sagratella; R Cipriani; S Mazzaferro; S Morano; M Sensi
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.